Stocks / NASDAQ / Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

Our Opinion

Moleculin Biotech, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following article that they conduct pre-clinical trials of their drugs on animals.

“In animal models designed to test cardiotoxicity, Annamycin was shown to be non-cardiotoxic.” Read the following article

Company Description

Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company, which focuses on the development of anti-cancer drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company’s preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms; and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe in July 2015 and is headquartered in Houston, TX. [Source: MarketWatch]

Company Website: